We are live on ! Find out more
PFM

Privium Fund Management Portfolio holdings

AUM $544M
1-Year Est. Return 72.49%
This Fund
S&P 500
This Quarter Est. Return
-13.18%
1 Year Est. Return
+72.49%
3 Year Est. Return
+451.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$480M
AUM Growth
-$62.8M
Cap. Flow
+$19.4M
Cap. Flow %
4.03%
Top 10 Hldgs %
63.98%
Holding
64
New
7
Increased
24
Reduced
17
Closed
4

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$10.4M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.38M
3
DNLI icon
Denali Therapeutics
DNLI
+$5.07M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.16M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$3.88M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$5.47M
2
MRK icon
Merck
MRK
+$3.85M
3
TSLA icon
Tesla
TSLA
+$2.68M
4
ARWR icon
Arrowhead Research
ARWR
+$1.98M
5
VZLA
Vizsla Silver
VZLA
+$1.12M

Sector Composition

Rank Sector Weight
1 Healthcare 33.85%
2 Consumer Discretionary 24.98%
3 Technology 24.21%
4 Financials 8.49%
5 Communication Services 6.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSLA icon
1
Tesla
TSLA
$1.36T
$82.5M 17.18%
222,000
-6,500
-3% -$2.68M
SHOP icon
2
Shopify
SHOP
$199B
$48.3M 10.05%
407,000
-3,000
-0.7% -$394K
SPOT icon
3
Spotify
SPOT
$107B
$32.5M 6.76%
67,000
-1,000
-1% -$502K
PLTR icon
4
Palantir
PLTR
$426B
$29.3M 6.09%
200,000
– –
AMZN icon
5
Amazon
AMZN
$2.85T
$26M 5.42%
125,000
+4,000
+3% +$881K
ARWR icon
6
Arrowhead Research
ARWR
$12B
$23M 4.79%
366,936
-31,268
-8% -$1.98M
IONS icon
7
Ionis Pharmaceuticals
IONS
$9.33B
$21.8M 4.53%
290,024
+49,200
+20% +$3.88M
LMND icon
8
Lemonade
LMND
$4.11B
$16M 3.33%
255,259
+7,000
+3% +$484K
NVDA icon
9
NVIDIA
NVDA
$5.45T
$14.1M 2.94%
81,000
– –
COIN icon
10
Coinbase
COIN
$39.3B
$13.8M 2.87%
79,000
– –
AMD icon
11
Advanced Micro Devices
AMD
$825B
$12.6M 2.63%
62,000
+2,000
+3% +$427K
ASTS icon
12
AST SpaceMobile
ASTS
$21.5B
$12M 2.5%
145,000
– –
SE icon
13
Sea Limited
SE
$75B
$11.4M 2.38%
138,000
– –
IREN icon
14
Iris Energy
IREN
$16.1B
$11M 2.28%
320,150
+40,150
+14% +$1.81M
AXSM icon
15
Axsome Therapeutics
AXSM
$11.1B
$9.93M 2.07%
58,729
+1,851
+3% +$320K
ESPR
16
DELISTED
Esperion Therapeutics
ESPR
$9.04M 1.88%
+3,299,441
New +$10.4M
PRQR icon
17
ProQR Therapeutics
PRQR
$260M
$8.86M 1.84%
5,467,149
+109,387
+2% +$179K
BIIB icon
18
Biogen
BIIB
$31B
$8.03M 1.67%
43,800
-29,680
-40% -$5.47M
QURE icon
19
uniQure
QURE
$3.25B
$7.95M 1.66%
486,520
+70,250
+17% +$1.42M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.57B
$7.64M 1.59%
364,802
+7,300
+2% +$164K
ARQT icon
21
Arcutis Biotherapeutics
ARQT
$3.23B
$7.56M 1.57%
320,972
+15,000
+5% +$383K
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$13.1B
$5.21M 1.09%
+92,305
New +$5.38M
VRTX icon
23
Vertex Pharmaceuticals
VRTX
$128B
$5.07M 1.06%
11,355
+2,000
+21% +$933K
DNLI icon
24
Denali Therapeutics
DNLI
$3.87B
$4.89M 1.02%
+254,857
New +$5.07M
URGN icon
25
UroGen Pharma
URGN
$2.3B
$4.28M 0.89%
238,122
+23,500
+11% +$471K
1
2 3

Similar funds

BCM
Brasada Capital Management Houston, Texas $545M AUM 18.58% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $547M AUM 20.34% 1-Year Est. Return
HIS
Harvest Investment Services Oakbrook Terrace, Illinois $547M AUM 64.58% 1-Year Est. Return
FMC
FTV Management Company San Francisco, California $541M AUM 34.37% 1-Year Est. Return
WCP
Wick Capital Partners Wayne, Pennsylvania $548M AUM 16.95% 1-Year Est. Return
CM
CoreCommodity Management Stamford, Connecticut $538M AUM 71.97% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return

Privium Fund Management's Q1 2026 Portfolio in Review

As of Q1 2026, Privium Fund Management held 64 positions worth $480M, down 12% from $543M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Privium Fund Management deployed $19.4M of net new capital in Q1 2026, opening 7 new positions and adding to 24 existing holdings. Its largest new stake was Esperion Therapeutics: 3,299,441 shares worth $9.04M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 29% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Biogen, an estimated $5.47M trimmed.

  • Privium Fund Management's largest Q1 2026 buy was Esperion Therapeutics: 3,299,441 shares worth $9.04M.
  • Privium Fund Management added most to Ionis Pharmaceuticals in Q1 2026, an estimated $3.88M increase.
  • Privium Fund Management's biggest Q1 2026 reduction was Biogen, cutting an estimated $5.47M.
  • Privium Fund Management fully exited Merck in Q1 2026, selling an estimated $3.85M.
  • Privium Fund Management's ten largest holdings make up 64% of its $480M portfolio in Q1 2026.
  • Privium Fund Management opened 7 new positions and closed 4 in Q1 2026.
  • Privium Fund Management's portfolio value fell 12% quarter-over-quarter to $480M.

Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.